ZBIO

Conviction 65HealthcareScan · Thu, Sep 24, 2026

Zenas BioPharma, Inc. (ZBIO) closed at $27.49 (-7.24%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 34, RS Rating 95, -36.3% from its 52-week high, -20.3% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

ZBIO$27.49-7.24%

ResistanceSupportVol 14Insider buy

Vol MA14 871.68K

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Zenas BioPharma, Inc.PHARMACEUTICAL PREPARATIONSwww.zenasbio.com ↗

Price27.49

Change-7.24%

Gap-0.07%

Rel volume5.17×

Avg volume776.71K

Avg $ vol24.1M

SMA 2031.85

SMA 5031.60

SMA 20025.60

Price vs 50-13.03%

Price vs 200+7.35%

MA stackmixed

50/200 cross—

Supertrenddown · 33.85

RSI (14)34

MACD hist-0.46

MACD cross—

Stoch %K / %D22 / 34

ADX (14)14

+DI / −DI17 / 34

RSI divergence—

MACD divergence—

ATR %7.09%

ADR %5.51%

52w high43.17

52w low15.20

From 52w high-36.33%

Above 52w low+80.82%

New 52w highNo

SqueezeFired

Bollinger width16.38%

%B-0.34

Donchian pos21.63%

Donchian high33.84

Donchian low25.73

AVWAP (52w high)23.86

vs AVWAP high+15.20%

AVWAP (52w low)23.74

vs AVWAP low+15.79%

OBV trendDown

Chaikin MF (20)-0.12

Today vs 20d5.17×

Avg vol (14d)871.68K

Avg vol (20d)776.71K

Avg $ vol (20d)24.1M

Market cap1.79B

RS Rating95 / 99

RS 3m (vs SPY)+6.92%

RS 6m (vs SPY)+7.04%

RS line new highNo

Trend template3/8

Technical rank53.7

1 week-14.03%

1 month-18.61%

3 months+11.41%

6 months+23.86%

1 year+44.96%

YTD-20.33%

P/E-4.74

P/B7.25

P/S179.14

P/FCF-10.39

EPS-8.44

Div yield—

ROE-152.87%

ROA-53.83%

Debt/Eq0.32

Current9.93

EV/EBITDA—

Gross margin—

Net margin—

Rev growth100.00%

EPS growth-140.62%

Price target43.40

Target upside57.90%

Analyst ratingBuy

Institutional92.54%

Ent. value1.67B

Revenue1M

Net income-111.46M

Gross profit—

Free cash flow-172.35M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out63.13M

Employees167

ListedFri, Sep 13, 2024

Free float22.65M

Float %39.5%

Short interest11.7M

Days to cover14.2d

Short volume53.7%

Squeeze score89 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$1.77 vs −$0.89

Last surprise-98.9% miss

Setup gradeB

Conviction65 / 100

Pattern quality—

Tech rank53.7 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance33.89

Support28.66

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ZBIO

All disclosures →

No recent disclosed trades by Congress in ZBIO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ZBIO · open-market 3 buys

Insider	Side	Shares	Value	Traded	Filed
Oliger Christy J. Director · Stock Option (Right to Buy) · 2026-09-01	Grant	37K	—	2026-09-01	2026-09-02
Allen Patricia L Director · Stock Option (Right to Buy) · 2026-06-15	Grant	18.5K	—	2026-06-15	2026-06-17
Boylan James P Director · Stock Option (Right to Buy) · 2026-06-15	Grant	18.5K	—	2026-06-15	2026-06-17
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-05-18	Other	—	—	2026-05-18	2026-05-18
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-05-18	Buy	60K	$1.0M	2026-05-18	2026-05-18
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-04-29	Buy	35K	$617K	2026-04-29	2026-04-29
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-04-28	Buy	25K	$451K	2026-04-28	2026-04-29
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-04-28	Other	—	—	2026-04-28	2026-04-29

SEC filings

EDGAR filings in ZBIO · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.